| Literature DB >> 32344662 |
Shen-Dar Chen1, Ying-Tzu Ju2, Yu-Jen Wei2, Min-Ling Hsieh2, Ching-Chuan Liu2, Jing-Ming Wu2, Jieh-Neng Wang2.
Abstract
Background and objective: Enterovirus 71 (EV 71) infections may result in the rapid progression of cardiopulmonary failure. Early endotracheal intubation is considered to be of primary importance. However, the appropriate timing for this is still not known. The aim of this study is to investigate the timing of intubation of children with fulminant EV71 infection. Material andEntities:
Keywords: emergency care; enterovirus 71; intubation; timing
Mesh:
Year: 2020 PMID: 32344662 PMCID: PMC7230837 DOI: 10.3390/medicina56040203
Source DB: PubMed Journal: Medicina (Kaunas) ISSN: 1010-660X Impact factor: 2.430
Comparison of enterovirus 71 (EV71) infection clinical stages and rhombencephalitis grades.
| World Health Organization (WHO) Guidelines * | Rhombencephalitis Grading ** | |
|---|---|---|
|
| Uncomplicated hand, foot, and mouth disease (HFMD)/Herpangina Stage | |
|
| HFMD with Central Nervous System (CNS) Involvement Stage | |
| Aseptic meningitis/Brainstem encephalitis/Encephalomyelitis | ||
| Most patients present with subtle neurologic symptoms or signs (e.g., drowsiness, limb weakness, ataxia, and myoclonic jerks) | ||
|
| HFMD with Autonomic Nervous System (ANS) Dysregulation Stage | |
| Tachycardia, hypertension, profound sweating, respiratory abnormalities | ||
|
| HFMD with Cardiopulmonary Failure Stage | |
| Hypotension/Shock, pulmonary edema/hemorrhage |
* by WHO, Reference [14]. ** by Huang CC, et al., Reference [9].
Comparison of demographic data and clinical presentations in intubated or non-intubated enterovirus 71 patients and their related outcome.
| Total Patient Number ( | Non-Intubated Patient Number ( | Intubation Patient Number ( | Poor Outcome * ( | |
|---|---|---|---|---|
| Age (months) | 30.7 ± 20.3 | 38.1 ± 22.2 | 23.5 ± 17.7 | 15.9 ± 12.7 *** |
| Oxygen saturation (SpO2) (%) | 95.5 ± 5.1 | 96.5 ± 4.8 | 93.2 ± 7.8 | 91.4 ± 6.1 |
| Myoclonus | 85 (81.0%) | 63 (84.0%) | 22 (73.3%) | 11 (78.5%) |
| Seizure | 21 (20.0%) | 14 (18.7%) | 7 (23.3%) | 3 (21.4%) |
| Irregular respiration | 19 (18.1%) | 1 (1.3%) | 18 (60.0%) | 12 (85.7%) *** |
| Ataxia | 20 (19.0%) | 14 (18.7%) | 6 (20.0%) | 2 (14.3%) |
| Cranial nerve involvement ** | 12 (11.4%) | 1 (1.3%) | 11 (36.6%) *** | 0 (0%) |
| Tachycardia | 58 (55.2%) | 32 (42.7%) | 26 (86.7%) *** | 12 (85.7%) |
| Hypertension | 34 (32.4%) | 23 (30.7%) | 11 (36.7%) | 4 (28.6%) |
| Hypotension/Shock | 14 (13.3%) | 0 (0%) | 14 (46.7%) | 14 (100%) *** |
* Poor outcome including death, ventilator-dependent, or vegetative with major neurological sequelae. ** Cranial nerve involvement including ocular disturbances (nystagmus, strabismus, or gaze paresis) and bulbar palsy (dysphagia, dysarthria, dysphonia, and facial weakness). *** p < 0.05 by Fisher’s exact test or one-way ANOVA test.
Comparison of intubation outcome by using rhombencephalitis grading and clinical staging in severe EV71 patients.
| Clinical Staging | Number of Patients | Number of Patients Received ETI (%) | Poor Outcome * | Rhombencephalitis Grading | Number of Patients | Number of Patients Received ETI (%) | Poor Outcome * |
|---|---|---|---|---|---|---|---|
| II | 43 | 1 (2.3%) | 0 (0%) | I | 77 | 3 (3.9%) | 0 (0%) |
| III | 45 | 13 (28.9%) | 0 (0%) | II | 10 | 9 (90%) ** | 0 (0%) |
| IV | 17 | 17 (100%) ** | 14 (87.5%) ** | III | 18 | 18 (100%) ** | 14 (83.3%) ** |
* Poor outcome including death, ventilator-dependence, or vegetative state with major neurological sequelae. ** p < 0.05 (by Fisher’s exact test).